Click to see our news releases about special projects and other announcements.Read More
Journalists: We are at your service. Please contact us with your request.Connect
To improve the efficacy of neoadjuvant immune checkpoint blockade against glioblastoma, researchers are looking for vulnerabilities in surgically removed tissues – a difficulty due to the vast differences within the tumor and between patients. To address this, ISB researchers and their collaborators developed a new way to study tumors.
The Baliga Lab’s Dr. Christopher Plaisier was the lead author of the study “Causal Mechanistic Regulatory Network for Glioblastoma Deciphered Using Systems Genetics Network Analysis” which published online in Cell Systems on July 14. Dr. Plaisier wrote a summary of the research: 3 Bullets: Using data from TCGA and ENCODE, ISB researchers developed integrative database and analysis platforms that provide insight about the underpinnings of glioblastoma multiforme. Researchers developed a…
By Varsha Dhankani Glioblastoma multiforme (GBM) is the most common and deadliest of malignant primary brain tumors in adults. Because of its lethality, GBM was selected as the first brain tumor to be sequenced as part of The Cancer Genome Atlas (TCGA), a comprehensive project funded by the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) to map the genomes of more than 25 types…